Taevas
South AfricaPharmaceuticals
Product Registration
Product Registration for Pharmaceuticals in South Africa
Taevas Global helps pharmaceutical manufacturers achieve SAHPRA registration efficiently, reducing time-to-market and ensuring full regulatory compliance in South Africa's growing medicines market.
Market
South Africa
Industry
Pharmaceuticals
Service
Product Registration
Regulator
SAHPRA
Timeline
12-24 months
What We Deliver
Six Pillars of South Africa Pharmaceuticals Intelligence
Our six interconnected pillars give pharmaceutical manufacturers a complete, actionable picture of the South African registration landscape from regulatory mapping through post-approval strategy.
01
Regulatory Pathway Analysis
We map every applicable SAHPRA registration pathway for your product category, whether new chemical entity, generic, biologic, or complementary medicine. Our team identifies the correct application module under the Medicines and Related Substances Act 101 of 1965 and its amendments. This prevents costly pathway misclassification before a single document is prepared.
Full-product classification under SAHPRA schedules
Pathway selection: new medicine, generic, or biosimilar
Identification of applicable CTD module requirements
How It Works
From Brief to Board-Ready Intelligence
Our four-stage engagement takes you from initial product assessment through a fully prepared SAHPRA submission package, with clear milestones and transparent communication at every stage.
Step 1 · Day 1-2
Product and Regulatory Assessment
We conduct an initial assessment of your product, its therapeutic category, existing dossier status, and any prior regulatory history. This scoping session identifies the correct SAHPRA registration pathway and surfaces any immediate red flags. You receive a written assessment summary within 48 hours of engagement.
Taevas Approach
The assessment covers product classification under the Medicines and Related Substances Act, identification of applicable SAHPRA guidance documents, review of existing clinical and quality data packages, and a preliminary gap analysis. We also assess whether any parallel African Union or WHO prequalification pathways could accelerate SAHPRA review under reliance procedures.
Market Snapshot
South Africa Pharmaceuticals Market at a Glance
$0B+
Pharmaceutical Market Size
0%
Projected Annual Growth Rate
0+
Licensed Manufacturers and Importers
0+
Products on the SAHPRA Register
Africa's Largest Pharma Market
South Africa is the largest pharmaceutical market on the African continent by value, accounting for roughly a third of total sub-Saharan African pharmaceutical sales. The country's established private healthcare sector and large public procurement programmes through the National Department of Health create dual commercial channels for registered medicines. This scale makes SAHPRA registration the most strategically important regulatory approval for any manufacturer targeting Africa.
SAHPRA Modernisation Under Way
SAHPRA, established as an autonomous entity in 2018 under the South African Health Products Regulatory Authority Act, has been progressively modernising its review processes including the introduction of eCTD submissions and reliance pathways aligned with WHO and stringent regulatory authority approvals. These reforms are gradually reducing review timelines for products with existing approvals from recognised regulators such as the EMA, FDA, or Health Canada. Manufacturers who structure their dossiers to leverage these reliance provisions gain a meaningful competitive timeline advantage.
Generic Medicine Dominance
Generic medicines account for the majority of prescription volumes in South Africa, driven by government procurement through the Essential Medicines List and the Single Exit Price regulatory pricing system. This creates a highly competitive but large-volume market for generic manufacturers who achieve SAHPRA registration. Biosimilar regulation is also developing, with SAHPRA publishing biosimilar guidelines that open pathways for biological product manufacturers.
Local Manufacturing Incentives
South Africa's Pharmaceutical Manufacturing Masterplan, supported by the Department of Trade, Industry and Competition, includes incentives for local manufacturing and technology transfer to reduce import dependency. Products manufactured locally or through approved South African contract manufacturers may benefit from preferential procurement in public tenders. This policy environment makes local manufacturing partnerships an increasingly attractive component of a South Africa market entry strategy.
What's Included
Everything in Your Registration Package
Every Taevas Global Product Registration engagement for South Africa delivers a comprehensive set of outputs designed to take your pharmaceutical product from initial assessment to SAHPRA approval.
Regulatory Pathway Report
A written report identifying the correct SAHPRA registration pathway for your product, including applicable legislation, guidance documents, and a preliminary timeline estimate.
CTD Dossier Gap Analysis
A module-by-module gap analysis of your existing documentation against SAHPRA requirements, with a prioritised action plan for closing each identified gap.
Compiled CTD Submission Package
A fully compiled and quality-reviewed CTD dossier in SAHPRA-accepted eCTD or NeeS format, including all South Africa-specific Module 1 administrative documents.
Labelling and PIL Compliance Package
Compliant outer carton text, inner label, and patient information leaflet drafted and reviewed against current SAHPRA labelling guidelines and scheduling requirements.
Local Agent and Responsible Pharmacist Briefing
Identification and engagement of a suitable South African responsible pharmacist or local agent, including a briefing document outlining their regulatory obligations.
SAHPRA Submission and Tracking
Formal lodgement of your application with SAHPRA, confirmation of receipt, and ongoing status tracking through the SAHPRA online portal with monthly status reports.
Deficiency Letter Response Management
Drafting, review, and submission of responses to any SAHPRA deficiency letters or additional information requests within agreed turnaround times.
Post-Approval Compliance Calendar
A structured post-registration compliance calendar covering pharmacovigilance reporting deadlines, annual renewal dates, and variation management obligations.
Who This Is For
Built for These Situations
Market Entry
International Manufacturer Entering South Africa
Your product is registered in Europe, the US, or Asia and you are ready to access South Africa's large and growing pharmaceutical market for the first time. You need a trusted partner who understands SAHPRA's specific requirements and can translate your existing dossier into a compliant South African submission without rebuilding from scratch. Taevas Global maps your existing approvals to SAHPRA reliance pathways to accelerate your timeline.
Outcome
Achieve first SAHPRA registration with a clear timeline and no regulatory surprises, leveraging existing approvals wherever SAHPRA reliance procedures apply.
Next Steps
After Product Registration, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Map Your South Africa Opportunity?
Speak with a Taevas Global regulatory specialist today to assess your SAHPRA registration pathway, understand your timeline, and build a market entry strategy tailored to your pharmaceutical product and commercial objectives.
Expert SAHPRA regulatory guidance from initial assessment to approval
Dossier preparation that reduces deficiency letters and delays
Access to vetted local responsible pharmacists and distribution partners
End-to-end post-registration compliance management for South Africa